Stevanato Group (NYSE:STVN – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Institutional and Insider Ownership
61.1% of Delcath Systems shares are held by institutional investors. 0.7% of Stevanato Group shares are held by insiders. Comparatively, 17.9% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Stevanato Group and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 13.43% | 14.31% | 8.18% |
| Delcath Systems | -2,308.86% | -563.60% | -111.13% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stevanato Group | $1.17 billion | N/A | $157.62 million | €0.59 ($0.63) | 44.83 |
| Delcath Systems | $2.07 million | 74.62 | -$47.68 million | ($2.97) | -1.87 |
Stevanato Group has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Stevanato Group has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Stevanato Group and Delcath Systems, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 2 | 5 | 0 | 2.71 |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
Delcath Systems has a consensus price target of $18.50, indicating a potential upside of 232.73%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Stevanato Group.
Summary
Stevanato Group beats Delcath Systems on 9 of the 13 factors compared between the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
